Cancer Res Treat.  2022 Oct;54(4):951-952. 10.4143/crt.2022.1326.

Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment

• Lee DH

• KMID: 2534175
• DOI: http://doi.org/10.4143/crt.2022.1326

Reference

References

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13:8–10.

2. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889; 133:571–3.

3. Fidler IJ, Poste G. The “seed and soil” hypothesis revisited. Lancet Oncol. 2008; 9:808.

4. Ewing J. Neoplastic diseases: a treatise on tumors. London: W.B. Saunders Co Ltd;1928.

5. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148:157–66.

6. Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al. NRG-BR002: a phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022; 40(16 Suppl):1007.

7. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21:e18–28.

8. Rim CH, Cho WK, Lee JH, Kim YS, Suh YG, Kim KH, et al. Role of local treatment for oligometastasis: a comparability based meta-analysis. Cancer Res Treat. 2022; 54:953–69.

9. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009; 139:1315–26.

10. Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011; 8:369–77.